BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company...
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases. According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BioCentury | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified a peptide-based inhibitor of the MYB-CREBBP interaction that could help treat AML. The inhibitor consisted of a retro-inverso form of a MYB...
BioCentury | Jan 5, 2018
Financial News

resTORbio proposes $85M IPO

resTORbio Inc. (Boston, Mass.) proposed on Dec. 29, 2017, to raise $85 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Leerink Partners, Evercore ISI and Wedbush PacGrow. In November, the aging-related disease...
BioCentury | Dec 21, 2017
Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research , researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that promoting...
Items per page:
1 - 10 of 71